For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| GammaCore Sham Device | Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study. | 0 | None | 0 | 29 | 5 | 29 | View |
| GammaCore Active Device | Subjects will use an Active GammaCore Device GammaCore Active Device | 0 | None | 2 | 30 | 6 | 30 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Altered sensations (brain zaps) | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Migratory Paresthesia | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Right arm (hand) tremor | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Right eye twitching | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Lip twiching | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Intermittent Vertigo | NON_SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | MedDRA | View |
| Lip numbness | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Nausea | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | MedDRA | View |
| Blister at treatment site | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| General malaise | NON_SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA | View |
| Sore throat | NON_SYSTEMATIC_ASSESSMENT | Infections and infestations | MedDRA | View |
| Urinary incontinence | NON_SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | MedDRA | View |
| Hoarseness | NON_SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA | View |
| Rash at treatment site | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| Itching | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| Worsening of migraine | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Blisters at treatment site | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| Rash/Blister at treatment site | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| Redness at treatment site | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| Rash | NON_SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | MedDRA | View |
| Exacerbated migraine | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Atypical migraine pain with associated blackouts | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |
| Mild pains in head and right arm | NON_SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA | View |
| Severe migraine | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA | View |